April-Monn, Simon Leonhard; Wiedmer, Tabea; Skowronska, Magdalena; Maire, Renaud; Schiavo Lena, Marco; Trippel, Mafalda; Di Domenico, Annunziata; Muffatti, Francesca; Andreasi, Valentina; Capurso, Gabriele; Doglioni, Claudio; Kim-Fuchs, Corina; Gloor, Beat; Zatelli, Maria Chiara; Partelli, Stefano; Falconi, Massimo; Perren, Aurel; Marinoni, Ilaria (2021). 3D Primary Cell Culture: A Novel Preclinical Model For Pancreatic Neuroendocrine Tumors (PanNETs). Neuroendocrinology, 111(3), pp. 273-287. Karger 10.1159/000507669
|
Text
April-Monn_et_al_Neuroendocrinology_BORIS_V2.pdf - Accepted Version Available under License Publisher holds Copyright. Download (9MB) | Preview |
Molecular mechanisms underlying the development and progression of PanNET are still insufficiently understood. Efficacy of currently approved PanNET therapies is limited. While novel treatment options are being developed, patient stratification permitting more personalized treatment selection in PanNET is yet not feasible since no predictive markers are established. The lack of representative in vitro and in vivo models as well as the rarity and heterogeneity of PanNET are prevailing reasons for this. In this study, we describe an in vitro 3D human primary PanNET culture system as a novel preclinical model for more personalized therapy selection. We present a screening platform allowing multi-center sample collection and drug screening in 3D cultures of human primary PanNET cells. We demonstrate that primary cells isolated from PanNET patients and cultured in vitro form islet-like tumoroids. Islet-like tumoroids retain the neuroendocrine phenotype and are viable for at least two weeks in culture with high success rate (86%). Viability can be monitored continuously allowing for a per-well normalization. In a proof-of-concept study, islet-like tumoroids were screened with three clinically approved therapies for PanNET: Sunitinib, everolimus and temozolomide. Islet-like tumoroids display varying in vitro response profiles to distinct therapeutic regimes. Treatment response of islet-like tumoroids (IC50) differs also between patient samples. We believe that the presented human PanNET screening platform is suitable for personalized drug testing in a larger patient cohort and a broader application will help in identifying novel markers predicting treatment response and in refining PanNET therapy.
Actions (login required)
 |
Edit item |